How are you counseling HR-proficient ovarian cancer patients about front line PARP inhibitor maintenance?  

Given recent approval of niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy

Answer from: Medical Oncologist at Academic Institution

Answer from: at Community Practice
Medical Oncologist at Northwest Medical Specialties PLLC
Thank you for the explanation. What is the PFS for...
at Baptist Medical Group
I agree. What is the PFS for BRCA and HRD negative...
Sign in or Register to read more